Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma.
Lingzhi HongWhitney E LewisMonique NilssonSonia A PatelSusan VargheseMelvin J RiveraRobyn R DuPingjun ChenHaley N KempWaree RinsurongkawongSimon HeekeAmy R SpelmanYasir Y ElaminMarcelo Vailati NegrãoBoris SepesiDon L GibbonsJ Jack LeeJia WuNatalie I VokesJohn V HeymachJianjun ZhangXiuning LePublished in: Cancers (2022)
This retrospective analysis revealed that immunotherapy provided limited additional benefit to chemotherapy in TKI-refractory EGFR-mutant LUAD. Chemotherapy alone or combined with bevacizumab remain good choices for patients with actionable EGFR mutations.